Exploring the Innovative Feeder-Free IL-2-Independent TIL Process by Juncell Therapeutics at ASGCT 2025 At the ASGCT Annual Meeting 2025, Juncell Therapeutics will present its breakthroughs in IL-2-independent TIL manufacturing, showcasing promising anti-tumor capabilities.

Exploring the Innovative Feeder-Free IL-2-Independent TIL Process by Juncell Therapeutics at ASGCT 2025 #China #Shanghai #Juncell_Therapeutics #TIL_therapy #IL-2-Independent

Juncell Therapeutics Unveils Promising TIL Therapy Data at AACR 2025 At the AACR Annual Meeting 2025, Juncell Therapeutics presented preclinical data showing innovative pretreatment methods for TIL therapy, highlighting hydroxychloroquine's role.

Juncell Therapeutics Unveils Promising TIL Therapy Data at AACR 2025 #China #Shanghai #Juncell_Therapeutics #TIL_therapy #AACR_2025

Juncell Therapeutics Unveils Cutting-Edge Facility to Advance Cancer Therapy Production Juncell Therapeutics has inaugurated a modern facility in Shanghai to enhance the production of innovative TIL therapies, paving the way for advancements in cancer treatment.

Juncell Therapeutics Unveils Cutting-Edge Facility to Advance Cancer Therapy Production #China #Shanghai #Juncell_Therapeutics #TIL_therapy